<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04602052</url>
  </required_header>
  <id_info>
    <org_study_id>StPaulsHMM</org_study_id>
    <nct_id>NCT04602052</nct_id>
  </id_info>
  <brief_title>Comparison of Surgical Versus Medical Termination of Pregnancy Between 13-20 Weeks of Gestation in Ethiopia</brief_title>
  <official_title>Comparison of Surgical Versus Medical Termination of Pregnancy Between 13-20 Weeks of Gestation in Ethiopia: A Quasi-experimental Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Paul's Hospital Millennium Medical College, Ethiopia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Paul's Hospital Millennium Medical College, Ethiopia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety and effectiveness of dilation and&#xD;
      evacuation for surgical abortion as compared to medical abortion&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients with a gestational age between 13-20 weeks are fully counseled on the risks and&#xD;
      benefits and given the option of medical or surgical abortion. Those who choose medical&#xD;
      abortion receive mifepristone 200 mg on day 1 and are appointed to return to SPHMMC 24-48&#xD;
      hours later for admission and misoprostol administration. Those who chose surgical abortion&#xD;
      are given mifepristone 200 mg with or without laminaria and appointed to return the next day&#xD;
      for surgical abortion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite complication rate</measure>
    <time_frame>During the abortion procedure and within 2 weeks post procedure</time_frame>
    <description>Presence of one of the following complications: bleeding requiring observation, genital tract lacerations requiring repair, need for additional intervention to complete the abortion procedure, and one or more symptoms of pelvic infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other serious maternal complications</measure>
    <time_frame>During the abortion procedure and within 2 weeks post procedure</time_frame>
    <description>Continued bleeding for more than two weeks, additional major surgery (laparotomy), and death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">279</enrollment>
  <condition>Termination of Pregnancy</condition>
  <arm_group>
    <arm_group_label>Medical arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Those who choose medical abortion receive mifepristone 200 mg on day 1 and are appointed to return to SPHMMC 24-48 hours later for admission and misoprostol administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those who chose surgical abortion are given mifepristone 200 mg with or without laminaria and appointed to return the next day for surgical abortion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dilation and evacuation</intervention_name>
    <description>Abortion is termination of pregannacy by evaccuating the uterus using either medical or surgical technique</description>
    <arm_group_label>Medical arm</arm_group_label>
    <arm_group_label>Surgical arm</arm_group_label>
    <other_name>Medical abortion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational age between 13 - 20 weeks confirmed with ultrasound,&#xD;
&#xD;
          -  Age at or more than18 years,&#xD;
&#xD;
          -  Having a working phone and willingness to be contacted for a follow-up questionnaire 2&#xD;
             weeks after the procedure.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Inability to give consent&#xD;
&#xD;
          -  complicated abortion (missed abortion, septic abortion)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Saint Paul's Hospital Millennium Medical College</name>
      <address>
        <city>Addis Ababa</city>
        <zip>1271</zip>
        <country>Ethiopia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ethiopia</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Paul's Hospital Millennium Medical College, Ethiopia</investigator_affiliation>
    <investigator_full_name>Tesfaye H. Tufa, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>Dilation and evacuation</keyword>
  <keyword>Second Trimester</keyword>
  <keyword>Medical abortion</keyword>
  <keyword>Ethiopia</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information can be shared up on request</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Currently available</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

